A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor α (TNFα) and abrogates endotoxin-induced lethality

Shock

Volumn 7, Issue 6, 1997, Pages 427-431

  Solorzano, Carmen C ^a   Ksontini, Riadh ^a   Pruitt, Jeffrey H ^a   Auffenberg, Troy ^a   Tannahill, Cynthia ^a   Galardy, Richard E ^b   Schultz, Gregory P ^a   MacKay, Sally L D ^a   Copeland III, Edward M ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDE; ENDOTOXIN; ILOMASTAT; METALLOPROTEINASE; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; FEMALE; HUMAN; METABOLISM; MORTALITY; MOUSE; SEPTIC SHOCK;

ANIMALS; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENDOTOXINS; FEMALE; HUMANS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; PROTEASE INHIBITORS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031154408     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199706000-00007     Document Type: Article

References (29)

1. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452, 1992.
2. Fong Y, Moldawer LL, Shires GT, and Lowry SF: The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 170:363-378, 1990.
3. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145:3762-3766, 1990.
4. Havell EA: Role of TNF in resistance to bacteria. Immunol Ser 56:341-363, 1992.
5. Molloy RG, Mannick JA, Rodrick ML: Cytokines, sepsis and immunomodulation. Br J Surg 80:289-297, 1993.
6. Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53:45-53, 1988.
7. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251-258, 1990.
8. Grell M, Douni E, Wajant H, et al: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802, 1995.
9. Gearing AJH, Beckett P, Chrostodoulou M, et al: Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370:555-557, 1994.
10. McGeehan GM, Becherer JD, Bast Jr RC, et al: Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370:558-560, 1994.
11. Grobelny D, Poncz L, Galardy RE: Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 31:7152, 1991.
12. Schultz GS, Strelow S, Stern GA, et al: Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases. Invest Ophthalmol Vis Sci 33:3325-3331, 1992.
13. Gijbels K, Galardy R, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-2182, 1994.
14. Wang P, Ba ZF, Galardy RE, Chaudry IH: A matrix metalloprotease inhibitor improves cardiovascular and hepatocellular function following hemorrhage and resuscitation. Shock 3(Suppl 2):35-36, 1995.
15. Barton BE, Jackson JV: Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 61:1496-1499, 1993.
16. Espevik T, Nissen Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-105, 1986.
17. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992.
18. Stuber F, Petersen M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis locus influences plasma tumor necrosis factor concentrations and outcome of patients with severe sepsis. Crit Care Med 24:381-384, 1996.
19. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM: Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 42:501-504, 1995.
20. Leeuwenberg JF, Dentener MA, Buurman WA: Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol 152:5070-5076, 1994.
21. Crowe PD, Walter BN, Mohler KM, Otten Evans C, Black RA, Ware CF: A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181:1205-1210, 1995.
22. Mullberg J, Durie FH, Otten Evans C, et al: A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p 60 TNF receptor. J Immunol 155:5198-5205, 1995.
23. Rothe J, Lesslauer W, Lotscher H, et al: Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802, 1993.
24. Galanos C, Freudenberg MA: Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology 187:346-356, 1993.
25. Freudenberg MA, Galanos C: Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galactosamine-treated mice. Infect Immun 59:2110-2115, 1991.
26. Solorzano CC, Ksontini R, Pruitt JH, et al: Involvement of 26 kD cell-associated TNF in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 158:414-419, 1997.
27. Van Zee KJ, Stackpole SA, Montegut WJ, et al: A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p 55 TNF receptor produces toxicity in the baboon. J Exp Med 179:1185-1191, 1994.
28. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W: Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177:1277-1286, 1993.
29. Tartaglia LA, Goeddel DV, Reynolds C, et al: Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 151:4637-4641, 1993.